Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petr Kocis

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
CNS Drugs|April 25, 2017
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical DataPetr Kocis, Martin Tolar, Jeremy Yu, et al.
Organic & Biomolecular Chemistry|August 23, 2011
Spirocyclic systems derived from pyroglutamic acidAndrew R Cowley, Thomas J Hill, Petr Kocis, et al.
CNS Drugs|November 14, 2018
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
CNS Drugs|August 5, 2018
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
Clinical Pharmacokinetics|October 25, 2017
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's DiseaseJohn A Hey, Jeremy Y Yu, Mark Versavel, et al.
Nature Reviews. Drug Discovery|April 2, 2016
Putting translational science on to a global stageC Taylor Gilliland, Dorit Zuk, Petr Kocis, et al.
ACS Pharmacology & Translational Science|April 8, 2020
The Fundamental Characteristics of a Translational ScientistC Taylor Gilliland, Julia White, Barry Gee, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
CNS Drugs|April 25, 2017
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical DataPetr Kocis, Martin Tolar, Jeremy Yu, et al.
Organic & Biomolecular Chemistry|August 23, 2011
Spirocyclic systems derived from pyroglutamic acidAndrew R Cowley, Thomas J Hill, Petr Kocis, et al.
CNS Drugs|November 14, 2018
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
CNS Drugs|August 5, 2018
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
Clinical Pharmacokinetics|October 25, 2017
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's DiseaseJohn A Hey, Jeremy Y Yu, Mark Versavel, et al.
Nature Reviews. Drug Discovery|April 2, 2016
Putting translational science on to a global stageC Taylor Gilliland, Dorit Zuk, Petr Kocis, et al.
ACS Pharmacology & Translational Science|April 8, 2020
The Fundamental Characteristics of a Translational ScientistC Taylor Gilliland, Julia White, Barry Gee, et al.
Pageof 1